Form 4: Revolution Medicines CEO Mark Goldsmith Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Revolution Medicines CEO Mark Goldsmith sold shares of common stock on April 10, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Mark Goldsmith, CEO of Revolution Medicines, sold shares of the company's common stock on April 10, 2024.
- The sales were executed under a 10b5-1 trading plan adopted on December 1, 2023.
- He sold 7,500 shares at a weighted average price of $35.4829.
- He also sold 5,000 shares at a weighted average price of $35.3317.
- Following these transactions, Goldsmith directly owns 452,879 shares.
- He indirectly owns 30,424 shares through the Jonathan Goldsmith Revocable Trust.
- He indirectly owns 30,424 shares through the Rebecca Eve Goldsmith Trust.
- He indirectly owns 327,547 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
- The filing also notes that Goldsmith holds 232,000 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating stock sales by an insider. It's a neutral event, especially given the pre-arranged trading plan.
Industry Context
Sales by company insiders are a common occurrence, especially when executed under pre-arranged trading plans like the 10b5-1 plan, which allows insiders to sell shares at predetermined times to avoid accusations of trading on non-public information.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2011-12-15 | Date of Goldsmith Children's 2011 Irrevocable Education Trust |
| 2023-12-01 | Date Mark A. Goldsmith adopted 10b5-1 trading plan |
| 2024-04-10 | Date of stock sale transactions |
| 2024-04-12 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.